Liver Cancer Market

Request Customization

Liver Cancer Market Research Report

Published: 2025 - Jan

Report Code: VMR-8530

Region: Global

Historic Range: 2022-2024

Forecast: 2025-2031

Format: Excel and PDF

Liver Cancer Market Analysis

The Liver Cancer Market represents a dynamic and rapidly advancing segment of oncology, addressing primary liver malignancies such as hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and rare variants like angiosarcoma. The market is shaped by breakthroughs in immunotherapies, targeted therapies, and innovative combination approaches to address unmet clinical needs in early, intermediate, and advanced stages of liver cancer. Precision medicine and novel treatment modalities are revolutionizing patient care, aiming to extend survival and improve quality of life.

Disruptive Impact and Opportunities:

The market is undergoing significant disruption, with novel mechanisms targeting immune checkpoint pathways, oncogenic signaling, and epigenetic regulation. These innovations introduce New therapeutic paradigms with improved efficacy and specificity, making advanced treatments Easier to administer via innovative delivery platforms. Moreover, the introduction of minimally invasive therapies enhances patient Safety, reducing side effects. Given the rising global burden of liver cancer and increasing investment in R&D, the market presents Big growth opportunities for stakeholders.

Liver Cancer Market Segmentation - Emerging Drugs

SRF388
MTL-CEBPA
APX3330
Fostroxacitabine bralpamide
CDX-527

Liver Cancer Market Segmentation - Marketed Drugs

CYRAMZA (ramucirumab)
KEYTRUDA (pembrolizumab)
TECENTRIQ (atezolizumab)
JEMPERLI (dostarlimab)
OPDIVO (nivolumab)
YERVOY (ipilimumab)

Key Companies:

Shanghai Henlius Biotech
Boehringer Ingelheim
Bristol-Myers Squibb
Jiangsu Hengrui Medicine
Glaxo SmithKline
ZAI Lab
Beijing Immunochina Medical Science and Technology
MiNA Therapeutics
Abbisko Therapeutics
Medivir AB
Teclison
Genoscience
Eureka Therapeutics

Liver Cancer Market Segmentation - By Type

Hepatocellular Carcinoma (HCC)
- Conventional HCC
- Fibrolamellar HCC
Intrahepatic Cholangiocarcinoma (ICC)
- Peripheral ICC
- Mass-Forming ICC
Hepatoblastoma
Angiosarcoma and Hemangiosarcoma
Others
- Mixed Hepatocellular-Cholangiocarcinoma
- Epithelioid Hemangioendothelioma

Liver Cancer Market Segmentation - By Administration Type

· Oral

Capsules
Tablets

· Injectable

Intravenous (IV)
Intramuscular (IM)
Intra-Arterial (IA)

· Others

Transarterial Chemoembolization (TACE)
Transarterial Radioembolization (TARE)

What’s in It for You?

Gain insights into the most promising emerging and marketed therapies shaping the liver cancer landscape.
Identify strategic partnerships with key companies at the forefront of innovation.
Understand growth opportunities in immunotherapies, precision medicine, and targeted delivery systems.
Develop data-driven strategies to optimize investments in this growing market.
Stay ahead of competition with detailed analysis of market trends and therapeutic advancements.

1.1 Introduction
1.2 Objectives
1.3 Key Findings

1.3.1 Market Size 2022 & 2032: By Key Country (10MM)
1.3.2 Global Market Size 2022 & 2032: By Key Segment
1.3.3 Key Investments & Startup Analysis

1.4 Research Methodology
2.1 Disease Overview
2.2 Classification
2.3 Signs and Symptoms
2.4 Risk Factors
2.5 Causes
2.6 Disease Biology & Digital Innovations
2.7 Stages & Staging System
2.8 Diagnostic Algorithm
2.9 Current Treatment Practices & Algorithm
2.10 Current Standard of Care and Treatment Gaps
2.11 Patient Demographics and Treatment Pathways
5.1 Epidemiology Key Findings
5.2 Assumptions and Rationale: 10MM
5.3 Epidemiology Scenario: 10MM
5.4 U.S. Epidemiology Scenario
5.5 EU-5 Epidemiology

5.5.1 U.K. Epidemiology Scenario
5.5.2 Germany Epidemiology Scenario
5.5.3 France Epidemiology Scenario
5.5.4 Italy Epidemiology Scenario
5.5.5 Spain Epidemiology Scenario

5.6 Japan Epidemiology Scenario
5.7 China Epidemiology Scenario
5.8 Australia Epidemiology Scenario
5.9 India Epidemiology Scenario
7.1 Existing Key Drug Candidate Profiles/ Marketed Therapies

7.1.1 CYRAMZA (ramucirumabis)

7.1.1.1 Product Description
7.1.1.2 Regulatory Milestones
7.1.1.3 Other Developmental Activities
7.1.1.4 Pivotal Clinical Trials
7.1.1.5 Ongoing Current Pipeline Activity

7.1.2 KEYTRUDA (pembrolizumab)

7.1.2.1 Product Description
7.1.2.2 Regulatory Milestones
7.1.2.3 Other Developmental Activities
7.1.2.4 Pivotal Clinical Trials
7.1.2.5 Ongoing Current Pipeline Activity

7.1.3 TECENTRIQ (atezolizumab)

7.1.3.1 Product Description
7.1.3.2 Regulatory Milestones
7.1.3.3 Other Developmental Activities
7.1.3.4 Pivotal Clinical Trials
7.1.3.5 Ongoing Current Pipeline Activity

7.1.4 JEMPERLI (dostarlimab)

7.1.4.1 Product Description
7.1.4.2 Regulatory Milestones
7.1.4.3 Other Developmental Activities
7.1.4.4 Pivotal Clinical Trials
7.1.4.5 Ongoing Current Pipeline Activity

7.1.5 OPDIVO (nivolumab)

7.1.5.1 Product Description
7.1.5.2 Regulatory Milestones
7.1.5.3 Other Developmental Activities
7.1.5.4 Pivotal Clinical Trials
7.1.5.5 Ongoing Current Pipeline Activity

7.2 Competitive Analysis and Differentiation
7.3 Overview of Similar/Competing Drugs in Clinical Trials
7.4 Future Trends and Emerging Drugs

7.4.1 SRF388

7.4.1.1 Product Description
7.4.1.2 Clinical Development
7.4.1.3 Safety and Efficacy

7.4.2 MTL-CEBPA

7.4.2.1 Product Description
7.4.2.2 Clinical Development
7.4.2.3 Safety and Efficacy

7.4.3 APX3330

7.4.3.1 Product Description
7.4.3.2 Clinical Development
7.4.3.3 Safety and Efficacy

8.1 Regulatory Pathways in Key Markets
8.2 Anticipated Regulatory Hurdles and Mitigation Strategies
8.3 Case Studies in Oncology Drug Regulation
8.4 Impact of Potential Changes to Regulatory Framework
9.1 Market Size & Growth Rates
9.2 Key Approvals & Anticipated Loss of Exclusivity
9.3 PESTLE & Porter’s Five Forces Analysis
9.4 Market Shares, Positioning/Ranking
9.5 Market Drivers
9.6 Identification of Threats
9.7 Digital Evolution in Commercialization
10.1 Market by Type

10.1.1 Hepatocellular Carcinoma
10.1.2 Cholangio Carcinoma
10.1.3 Hepatoblastoma
10.1.4 Others

10.2 Market by Therapy Type

10.2.1 Targeted Therapy
10.2.2 Immunotherapy
10.2.3 Chemotherapy

11.1 Competitive Pricing Analysis
11.2 Reimbursement Landscape and Challenges
11.3 Strategies for Market Access and Equity
11.4 Patient Spending/Expenditure Analysis
12.1 Analysis of Emerging Trends
12.2 Technological Impact
12.3 Impact of Potential Market Disruptors
12.4 Opportunities for Future Development and Expansion
12.5 Considerations for Investment Opportunities
13.1 Regional Regulatory Disparities
13.2 Cross-Border Partnership Strategies
13.3 Global Supply Chain Dynamics
13.4 Case Studies: Success and Failure in Global Markets
13.5 Strategies for Global Expansion and Localization
14.1 Shanghai Henlius Biotech
14.2 Boehringer Ingelheim
14.3 Bristol-Myers Squibb
14.4 Jiangsu Hengrui Medicine
14.5 GlaxoSmithKline
14.6 MiNA Therapeutics
14.7 Medivir AB
14.8 Takeda
14.9 Imunon, Inc.
14.10 Avant Immunotherapeutics, Inc.

📥 Download Sample Report

Fill out the form below and our team will get back to you shortly

The field with (*) is required.

📋 Contact Information

Name *

Email *

Company *

Job Title *

Country *

Phone *

Message (Optional)

Security Verification

This form is protected by Google reCAPTCHA v3. Verification runs automatically when you submit.

Your information is secure and will not be shared with third parties.

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

Select User License Type

Data Spreadsheet: Market data delivered in spreadsheet format for analysis.

Single User: One named user; PDF report access for internal use.

Multi User: Up to five users within the same organization at one location.

Corporate User: Enterprise-wide access across your organization.

Data Spreadsheet

2500

Single User

4250

Multi User

5250

Corporate User

6900

Country-Specific Report

Dive into Country Outlook

Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.

Access Country Insights

Testimonials

“We received a complex piece of work for our niche market from Virtue Market research in short period of time. I appreciate the quality and content of the final files we received. Thanks for the support”

Medical Devices Company based in Europe